- Green Growth
- Your Consultant
|GSK House London in the UK|
According to Dan Millard, chief representative of GSK Vietnam, the group is donating $10 million to the World Health Organization (WHO) and the UN Foundation’s COVID-19 Solidarity Response Fund to support WHO and partners in preventing, detecting, and managing the pandemic, particularly where the needs are the greatest.
In regard to the expansion of vaccines collaborations, GSK is now working with five partner companies and research groups across the world, including in the USA and China. This builds on its previous announcements regarding partnerships with the University of Queensland and Clover Biopharmaceuticals to make its vaccine adjuvant technology available to support their respective COVID-19 vaccine research programmes.
The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced, and therefore contributing to the protection of more people.
GSK is also entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from its libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.
|Scientist in at GSK's R&D department|
“We are also evaluating our marketed medicines and those in development to determine if any could be used beyond their current indications, and evaluating options to make available our specialised laboratory space to help in the research and testing of COVID-19,” said Dan Millard.
GSK is also donating surplus reagents to countries to support diagnostic testing and is preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees to enable those with medical or specialist expertise to provide support to frontline health workers and national governments.
Specifically, GSK Consumer Healthcare is prioritising actions in its supply chain to deliver more consumer products that are in high demand due to COVID-19. This includes increasing the production for pain relief brands such as Paracetamol, multi-vitamins, and dietary supplements.
“We continue to monitor the situation closely and take action to develop our response to the pandemic. In doing so, we will continue to put the needs of patients and our people first at all times,” he added.
In Vietnam, GSK has been present for over 25 years, affirming its role and mission to improve quality for Vietnamese people over the past years, and gained great success there.
|US groups flock to ASEAN to further aid business interests|
|GSK supporting Vietnamese healthcare for 25 years|
|GSK prepares to grasp opportunities from EVFTA|